Scientific
publications

Working closely with our partnered centres and universities, our researchers contribute to the progress of Life Sciences knowledge.

Allegretti M. Ruffini P. A. D’Anniballe G. Brandolini L. Bertini R. Aramini A. Antonosante A. Ferrari M. P. Mantelli F. Beccari A. Noncompetitive allosteric inhibitors of the inflammatory chemokine... CXCR1/2 inhibition enhances pancreatic islet... Safety and pharmacokinetics of escalating... Tumor-Produced Interleukin-8 Attracts... Targeting CXCR1 on breast cancer stem... Targeting the minor pocket of C5aR... CXCR1 and CXCR2 Chemokine Receptor... CXCR1/2 pathways in paclitaxel-induced... Phase II Randomized, Double-Masked... CXCR1/2 Inhibition Blocks and... Role of the chemokine receptor... Receptor binding mode and... Therapeutic inhibition of CXCR2 by... Phase Ib Pilot Study to Evaluate... Chemokine Signaling in... Blockade of the chemokine receptor... Allosteric inhibitors of chemoattractant... Topical Recombinant Human Nerve... CXCR1/2 Antagonism Is Protective... Autocrine CXCL8-dependent... Phase I Trial of Recombinant... Intravital Microscopic Evaluation of... A window-of-opportunity trial of the... The Novel C5aR Antagonist DF3016A... IL-6 and CXCL8 Mediate... Multiple Anti-Tumor Effects of Reparixin... Ladarixin, a Dual CXCR1/2 Inhibitor... CXCR1 and CXCR2 Inhibition by Ladarixin... Targeting CXCR1/2 does not improve insulin... CXCR2 Is Critical for Bacterial Control and... Emerging Role of C5 Complement Pathway in... Inhibition of osteoclast activity by complement... A randomized, placebo-controlled phase 2 study of paclitaxel... Islet allotransplantation in type 1 diabetes: Phase 2 pilot study with... CXCR2 inhibition improves islet transplantation Effect of topical recombinant human nerve growth factor... IL6 and CXCL8 mediate redundant, targetable tumor-host interactions... Phase I, randomized, double-masked, vehicle-controlled study to evaluate safety... Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in... Tooltip
All Ophthalmology Diabetology Pain and Inflammation Oncology Food Supplements Antitussive Drugs Preclinical Programs SARS-CoV-2

Frontiers in Oncology December 2022

The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance

Mara Zippoli, Anna Ruocco, Rubina Novelli, Francesca Rocchio, Martina Sara Miscione, Marcello Allegretti, Maria Candida Cesta and Pier Giorgio Amendola

Science Advances November 2022

The SARS-CoV-2 spike protein binds and modulates estrogen receptors

Oscar Solis, Andrea R. Beccari, Daniela Iaconis, Carmine Talarico, Camilo A. Ruiz-Bedoya, Jerome C. Nwachukwu, Annamaria Cimini, Vanessa Castelli, Riccardo Bertini, Monica Montopoli, Veronica Cocetta, Stefano Borocci, Ingrid G. Prandi, Kelly Flavahan, Melissa Bahr, Anna Napiorkowski, Giovanni Chillemi, Masato Ooka, Xiaoping Yang, Shiliang Zhang, Menghang Xia, Wei Zheng, Jordi Bonaventura, Martin G. Pomper, Jody E. Hooper, Marisela Morales, Avi Z. Rosenberg, Kendall W. Nettles, Sanjay K. Jain, Marcello Allegretti, Michael Michaelides

Nature - British Journal of Cancer November 2022

CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer

Geny Piro, Carmine Carbone, Antonio Agostini, Annachiara Esposito, Maria De Pizzol, Rubina Novelli, Marcello Allegretti, Andrea Aramini, Alessia Caggiano, Alessia Granitto, Francesco De Sanctis, Stefano Ugel, Vincenzo Corbo, Maurizio Martini, Rita Teresa Lawlor, Aldo Scarpa, Giampaolo Tortora

MDPI - International Journal of Molecular Sciences October 2022

The Spike Mutants Website: A Worldwide Used Resource against SARS-CoV-2

Isabella Romeo, Ingrid Guarnetti Prandi, Emanuela Giombini, Cesare Ernesto Maria Gruber, Daniele Pietrucci, Stefano Borocci, Nabil Abid, Anna Fava, Andrea R. Beccari, Giovanni Chillemi, Carmine Talarico

Cornell University October 2022

EXSCALATE: An extreme-scale in-silico virtual screening platform to evaluate 1 trillion compounds in 60 hours on 81 PFLOPS supercomputers

Davide Gadioli, Emanuele Vitali, Federico Ficarelli, Chiara Latini, Candida Manelfi, Carmine Talarico, Cristina Silvano, Carlo Cavazzoni, Gianluca Palermo, Andrea Rosario Beccari

European Journal of Immunology October 2022

Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis

Maria Candida Cesta, Mara Zippoli, Carolina Marsiglia, Elizabeth M. Gavioli, Giada Cremonesi, Akram Khan, Flavio Mantelli, Marcello Allegretti, Robert Balk

MDPI - International Journal of Molecular Sciences September 2022

Exscalate4CoV: Innovative High Performing Computing (HPC) Strategies to Tackle Pandemic Crisis

Andrea R. Beccari, Giulio Vistoli

Pain & Therapy September 2022

Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis

Maria C Spera, Maria C Cesta, Mara Zippoli, Giustino Varrassi, Marcello Allegretti

Frontiers in Cell and Developmental Biology August 2022

The role of C5a-C5aR1 axis in bone pathophysiology: A mini-review

Anna Ruocco, Anna Sirico, Rubina Novelli, Silvia Iannelli, Shane Vontelin Van Breda, Diego Kyburz, Paul Hasler, Andrea Aramini, Pier Giorgio Amendola

Internation Journal of Molecular Sciences August 2022

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins

Ingrid Guarnetti Prandi, Carla Mavian, Emanuela Giombini, Cesare E. M. Gruber, Daniele Pietrucci, Stefano Borocci, Nabil Abid, Andrea R. Beccari, Carmine Talarico, Giovanni Chillemi
Dompé logo

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153

Close